A recent non-binding governance poll on Starknet showed 93.52% of participants backing research into developing an independent post-quantum Layer-1 blockchain. This move aims to prepare Starknet for future quantum computing challenges without committing to any immediate chain migration. The result highlights the community's interest in advancing blockchain security and technology to withstand quantum threats, signaling potential future innovation in the ecosystem.
The recent Starknet governance poll showed 93.52% support for researching a post-quantum Layer-1 blockchain. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 02:31 WIB: out of 50 major cryptocurrencies, 36 rose and 13 fell today. Notable movers include COTI at Rp202 (+3.90%, 84% Sell / 16% Buy), VET at Rp130 (+3.33%, 88% Sell / 12% Buy), and ATOM at Rp31,613 (+2.92%, 54% Sell / 46% Buy).
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
